SVB Leerink Maintains Outperform on Aligos Therapeutics, Raises Price Target to $11
SVB Leerink analyst Roanna Ruiz maintains Aligos Therapeutics (NASDAQ:ALGS) with a Outperform and raises the price target from $10 to $11.
Aligos Therapeutics Q4 EPS $(0.89) Misses $(0.83) Estimate
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(0.89) per share which missed the analyst consensus estimate of $(0.83) by 7.23 percent. This is a 18.35 percent increase over losses of $(1.09) per share
Aligos Therapeutics Earnings Preview
Aligos Therapeutics (NASDAQ:ALGS) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement.
Analysts estimate that Aligos Therapeutics will report an earnings per share (EPS) of $-0.83.
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 147 companies achieved new lows for the year.
10 Biggest Price Target Changes For Wednesday
Needham raised Airbnb, Inc. (NASDAQ: ABNB) price target from $210 to $220. Airbnb shares rose 3.1% to $185.70 in pre-market trading.
Aligos Therapeutics Begins Dosing In Chronic Hepatitis B Patients In Its Phase 1 Antisense Oligonucleotide Study
Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the first
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
Aligos Therapeutics Expands Collaboration With Merck To Develop Oligonucleotide Therapies For NASH
Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has
56 Biggest Movers From Friday
Gainers
Hour Loop, Inc. (NASDAQ: HOUR) shares jumped 99.8% to $7.99 after the company priced its IPO at $4 per share.